3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts (4th Edition), 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2022

  • Pages
    481

  • View Count
    9014

Example Insights

3D-Cell-Culture-Market-Context-thumb 3D-Cell-Culture-Market-Evolution-of-The-Market-thumb 3D-Cell-Culture-Market-List-of-Products-thumb 3D-Cell-Culture-Market-Distribution-by-Status-of-Development-thumb 3D-Cell-Culture-Market-Distribution-of-Companies-by-Location-of-Headquarters-thumb
3D-Cell-Culture-Market-Bioreactors-List-of-Products-thumb 3D-Cell-Culture-Market-Product-Competitiveness-Analysis-thumb 3D-Cell-Culture-Market-Partnerships-and-Collaborations-thumb 3D-Cell-Culture-Market-Funding-and-Investments-thumb 3D-Cell-Culture-Market-Patent-Analysis-thumb
3D-Cell-Culture-Market-Publication-Analysis-thumb 3D-Cell-Culture-Market-Distribution-by-Type-of-Product-thumb 3D-Cell-Culture-Market-Distribution-by-Purpose-thumb    

Overview

Animal testing has been the most common method in various experimental studies in biomedical research, given their resemblance to humans in terms of genetics, anatomy, and physiology. Specifically, mice genome has 80% similarity with humans, which makes them excellent models for various research purposes. However, the use of animals in scientific research is associated with several ethical concerns, which led to the establishment of the principle of 3Rs- Replacement, Reduction and Refinement, to address the ethical concerns related to animal welfare and limit the use of animals in scientific research. As of 2018, this initiative led to 50% reduction in the use of animals as compared to the statistics noted in 1985. Further, the process of animal breeding / housing for scientific purposes is also associated with high costs and requires skilled labor. Moreover, it has been demonstrated that animal cell cultures are unable to accurately mimic the natural (in vivo) microenvironment as the cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. These concerns have necessitated a transition from animal-based testing to the use of 3-dimensional (3D) cell culture models. Over time, advances in biotechnology and materials science have enabled the development of a variety of 3D cell culture systems in order to drive research across different application areas, including cancer research, drug discovery, tissue engineering and others. 

At present, more than 140 companies offer 3D cell culture systems in a variety of formats, including scaffold-based products, scaffold-free products and 3D bioreactors. These systems have demonstrated to be capable of more accurately simulating the natural tissue microenvironment, offer increased cell-to-cell and cell-to-ECM interactions, more accurate evaluation of drug toxicity and cellular responses, and co-cultuirng of multiple cell types together. Moreover, there are certain complex 3D cell culture models that can even replace animal models exhibiting reproducible results and thereby, serving as better in vivo models across multiple application areas. Given the various benefits of such systems, the field has garnered the attention of various venture capital firms and strategic investors that have been providing financial support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ-on-chips across multiple application areas. Moreover, there has been an increase in scientific literature on 3D cell culture systems and collaborations for 3D bioreactors and cell culture products. Given the ongoing innovation in this field, and the paradigm shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness a significant growth in the foreseen future.

Scope of the Report

The “3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (4th Edition), 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of the market in the mid to long term. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. 
  • An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
  • An overview of the current market landscape of companies offering various 3D cell culture systems, including information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
  • A detailed assessment of the overall landscape of scaffold based products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of scaffold (human based, chemical based, animal based, plant based, and polymer based), and fabrication material used. In addition, it presents details of the companies involved in the development of scaffold based products, providing information on their year of establishment, company size, and location of headquarters.
  • A detailed assessment of the overall landscape of scaffold free products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), type of  material (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies involved in the development of scaffold free products, providing information on their year of establishment, company size, and location of headquarters.
  • A detailed assessment of the overall landscape of 3D bioreactors, along with analyses based  on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), status of development (under development, developed and not commercialized, and commercialized), typical working volume, scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of manufacturing process (batch-continuous, fed-batch and continuous), type of cell culture system (mammalian cell, insect cell, microbial cell, and plant cell), type of molecule processed (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research). In addition, it presents details of the companies involved in the development of 3D bioreactors, providing information on their year of establishment, company size, and location of headquarters.
  • A detailed review of the key application areas (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. 
  • Elaborate profiles of prominent players offering Scaffold-based, Scaffold-free cell culture systems and 3D bioreactors (shortlisted based on the number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile includes a brief overview of the company, financial / funding information (if available), details on its product portfolio, recent developments, and an informed future outlook.
  • An analysis of the investments made in the period between 2016-2022, including instances of seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products. 
  • An analysis of the various partnerships related to 3D cell culture products, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (product development and commercialization agreements, product integration and utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
  • An in-depth analysis of over 6,400 patents that have been filed / granted for 3D cell culture products, between 2016-2021, based on parameters, such as type of patent, publication year, issuing authority involved, CPC symbols, type of applicant, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis. 
  • An analysis of more than 3,800 peer-reviewed scientific articles related to 3D cell culture and its technologies, published since 2019, based on several parameters, such as year of publication, emerging focus areas, most popular authors,  and most popular journals (in terms of number of articles published in the given time period and journal impact factor), top publisher and type of funding institute.
  • An in-depth competitiveness analysis of 3D bioreactors, taking into consideration the supplier power (based on the year of establishment of the 3D bioreactors developer) and key features of bioreactors, such as scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of molecule supported (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy),  type of cell culture supported (mammalian cell, insect cell, microbial cell, and plant cell) and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine/tissue engineering and cancer research).
  • A case study on the 3D cell culture products for organoids and organ-on-chips, along with analysis based on parameters, such as status of development, and area of applications. In addition, it presents details of the developer companies, along with information on their year of establishment, company size, and location of headquarters.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products, emphasized on the focus area of their company, type of 3D cell culture products offered, development status of the product(s), method of fabrication used, source of 3D cultured cells, application area of product(s), type of service(s) offered, and present and future market opportunity.

One of the key objectives of the report was to identify the primary growth drivers and estimate the potential future size of the 3D cell culture market. Based on various parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have developed informed estimates on the likely evolution of the 3D cell culture systems market, for the period 2022-2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across 3D cell culture format (scaffold based systems, scaffold free systems, and 3D bioreactors), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), purpose (research use and therapeutic use), key geographical regions (North America, Europe, Asia-Pacific,  Latin America, MENA and rest of the world), and leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players: 

  • Brigitte Angres (Co-founder, Cellendes)
  • Bill Anderson (President and CEO, Synthecon)
  • Anonymous (President and CEO, Anonymous)
  • Anonymous (Co-founder and Vice President, Anonymous)
  • Scott Brush (Vice President, BRTI Life Sciences)
  • Malcolm Wilkinson (Managing Director, Kirkstall)
  • Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
  • Tanya Yankelevich (Director, Xylyx Bio)
  • Jens Kelm (Chief Scientific Officer, InSphero)
  • Walter Tinganelli (Group Leader, GSI)
  • Darlene Thieken (Project Manager, Nanofiber Solutions)
  • Andrea Picon (Director, Business Development, FlexCell International)
  • Frank Junker (Chief Business Officer, InSphero)
  • Mohammed Mamunur Rahman (Manager, Business Development, MBL International)

Key Questions Answered

  • Who are the leading industry players engaged in the development of 3D cell culture products?
  • Which are the most popular 3D cell culture products?
  • Which are the different application areas for which 3D cell culture products are being developed?
  • What are the key factors that are likely to influence the evolution of 3D cell culture systems market?
  • What is the trend of capital investments in the 3D cell culture systems market?
  • Which partnership models are commonly adopted by stakeholders in 3D cell culture market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to 3D cell culture systems market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state and the likely evolution of the 3D cell culture systems market in the mid to long term. 

Chapter 3 provides a general introduction to 3D cell culture systems. The chapter presents information on the different types of cell cultures, methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, namely scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also provides insights on the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summary of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. In addition, the chapter provides information on the working principle, benefits and limitations associated with each method used for fabricating scaffolds. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on around 140 industry players offering various 3D cell culture products. It features detailed analyses of developers, based on year of establishment, company size, location of headquarters, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides different insightful representations, which include [A] a heat map representation, illustrating the distribution of developers, based on 3D cell culture format and location of headquarters, [B] tree map representation, presenting the distribution of developers, based on type of product and company size, and [C] world map representation, highlighting the regional distribution of headquarters of the developer companies.

Chapter 7 presents information on around 200 scaffold based products that are either commercialized or under development. It features detailed analysis of these products based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized) type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of scaffold (human based, chemical based, animal based, plant based, and polymer based), and fabrication material. In addition, it presents details of the companies involved in the development of scaffold based products, providing information on their year of establishment, company size, and location of headquarters.

Chapter 8 presents information on around 40 scaffold free products that are either commercialized or under development. It features detailed analysis of these products based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), type of material (human based, animal based, plant based and polymer based), and material used of fabrication. In addition, it presents details of the companies involved in the development of scaffold free products, providing information on their year of establishment, company size, and location of headquarters.

Chapter 9 presents information on around 90 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), status of development (under development, developed and not commercialized, and commercialized), typical working volume, scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of manufacturing process (batch-continuous, fed-batch and continuous), type of cell culture system (mammalian cell, insect cell, microbial cell, and plant cell), type of molecule processed (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research). In addition, it presents details of the companies involved in the development of 3D bioreactors, providing information on their year of establishment, company size, and location of headquarters.

Chapter 10 presents information on the key application areas (cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. 

Chapter 11 features elaborate profiles of prominent players engaged in the development of scaffold based products (offering at least five hydrogel / ECM products). Each company profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players engaged in the development of scaffold free products (offering at least three scaffold free cell culture products). Each company profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that engaged in the development of 3D bioreactors (offering at least two bioreactors). Each company profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2016-2022, including instances of seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.

Chapter 15 features an analysis of the various partnerships related to 3D cell culture products, that have been established since 2015, based on several parameters, such as year of agreement, type of partnership (product development and commercialization agreements, product integration and utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth analysis of over 6,400 patents that have been filed / granted for 3D cell culture products, between 2016-2021, based on parameters, such as type of patent, publication year, issuing authority involved, CPC symbols, type of applicant, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis. 

Chapter 17 features an analysis of more than 3,800 peer-reviewed scientific articles related to 3D cell culture and its technologies, published since 2019, based on several parameters, based on several parameters, such as year of publication, emerging focus areas, most popular authors,  and most popular journals (in terms of number of articles published in the given time period and journal impact factor), top publisher and type of funding institute.

Chapter 18 features an insightful competitiveness analysis of 3D bioreactors, taking into consideration the supplier power (based on the year of establishment of the 3D bioreactors developer) and key features of bioreactors, such as scale of operation (lab scale, pre-clinical/clinical scale and commercial scale), type of molecule supported (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy),  type of cell culture supported (mammalian cell, insect cell, microbial cell, and plant cell) and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research).

Chapter 19 is a case study providing an overview on the current market landscape of 3D cell culture products for organoids and organ-on-chips, along with analysis based on parameters, such as development status, and area of application. In addition, it presents details of the developer companies, along with information on their year of establishment, company size, and location of headquarters.

Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, till 2035. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture format (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world), and [F] leading product developers.

Chapter 21 presents insights from the survey conducted for this study. We contacted over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 22 is a summary of the overall report. It presents a list of key takeaways and our independent opinions on the current market scenario.

Chapter 23 is a collection of interview transcripts of the discussions held with various stakeholders in the industry. We have presented details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions), Andrea Picon (Director, Business Development, FlexCell International), Frank Junker (Chief Business Officer, InSphero) and Mamun Rahman (Manager, Business Development, MBL International)

Chapter 24 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 25 is an appendix, that provide the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines

3.3. Morphology of Cells in Culture
3.4. 2D Cell Cultures vs 3D Cell Cultures

3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format

3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing / Passaging 
3.6.4. Cryogenic Storage

3.7. Requirements for Maintaining Healthy Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Cross Contamination in Cell Cultures
3.7.4. Methods to Prevent Contamination

3.8. Applications of 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research

3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives

4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS 
4.1. 3D Cell Culture Classification
4.2. Scaffold Based 3D Cell Cultures
4.2.1. Hydrogels / ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers

4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors

4.4. Organoids

5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering

5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding

5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization / Crosslinking
5.4.6. Microfluidics

5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping / Solid Free-Form Technique

5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation

5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization

6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format 
6.2.5. Analysis by Type of Product
6.2.6. Analysis by 3D Cell Culture Format and Location of Headquarters
6.2.7. Analysis by Company Size and Type of Product
6.2.8. Analysis by Location of Headquarters

6.3. 3D Cell Cultures: List of Service Providers
6.4. 3D Cell Cultures: List of Affiliated Assays, Kits and Reagents

7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold Based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of Scaffold
7.2.4. Analysis by Material Used for Fabrication
7.2.5. Analysis by Type of Product and Source of Scaffold
7.2.6. Analysis by Type of Product and Material Used for Fabrication

7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Company Size and Type of Product
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Developers: Analysis by Number of Scaffold Based Products

8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Material Used for Fabrication
8.2.4. Analysis by Material Used for Scaffold
8.2.5. Analysis by Type of Product and Material Used for Fabrication

8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Company Size and Type of Product
8.3.4. Analysis by Location of Headquarters
8.3.5. Leading Developers: Analysis by Number of Scaffold Free Products

9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Status of Development
9.2.3. Analysis by Working Volume
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Manufacturing Process
9.2.6. Analysis by Type of Cell Culture System
9.2.7. Analysis by Type of Molecule Processed
9.2.8. Analysis by Area of Application

9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Leading Developers: Analysis by Number of 3D Bioreactors 

10. KEY APPLICATION AREAS 
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Cancer Drug Screening with 3D Culture Systems

10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models

10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation

10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering

10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold Based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas

11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook

11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook

11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook

11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook

11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook

12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIPS DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook

12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook

12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook

12.1.4. MIMETAS
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook

12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook

13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook

13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook

13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook

13.5. EBERS
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook

13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook

13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook

13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Summary of Funding and Investments

15. PARTNERSHIPS AND COLLABORATIONS 
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: List of Partnerships and Collaborations 
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership

15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner

15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format

15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product

15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements

16. PATENT ANALYSIS 
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Type of Patent and Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Analysis by Type of Applicant
16.3.6. Word Cloud Analysis: Emerging Focus Areas
16.3.7. Leading Industry Players: Analysis by Number of Patents
16.3.8. Leading Non-Industry Players: Analysis by Number of Patents

16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations

17. PUBLICATION ANALYSIS
17.1. 3D Cell Culture Systems: Publication Analysis
17.2. Assumptions and Key Parameters
17.3. Methodology
17.3.1. Analysis by Year of Publication
17.3.2. Word Cloud Analysis: Emerging Focus Areas
17.3.3. Top Authors: Analysis by Number of Publications
17.3.4. Key Journals: Analysis by Number of Publications
17.3.5. Key Publishers: Analysis by Number of Publications
17.3.6. Leading Funding Institutes: Analysis by Number of Publications

18. PRODUCT COMPETITIVENESS ANALYSIS
18.1. Chapter Overview
18.2. Assumptions / Key Parameters
18.3. Methodology
18.4. Product Competitiveness Analysis: 3D Bioreactors
18.4.1. Companies Headquartered in North America
18.4.2. Companies Headquartered in Europe
18.4.3. Companies Headquartered in Asia-Pacific and Rest of the World

19. CASE STUDY: ORGANIDS AND ORGAN-ON-CHIPS
19.1. Chapter Overview
19.2. Organoids and Organ-on-Chips: List of Products
19.2.1. Analysis by Status of Development
19.2.2. Analysis by Application Area

19.3. Organoids and Organ-on-Chips: List of Product Developers
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Company Size
19.3.3. Analysis by Location of Headquarters

20. MARKET FORECAST
20.1. Chapter Overview
20.2. Key Assumptions and Forecast Methodology
20.3. Global 3D Cell Culture Market, 2022-2035

20.4. Global 3D Cell Culture Market: Distribution by Business Segment
20.4.1. 3D Cell Culture Systems Market, 2022-2035
20.4.2. 3D Cell Culture Consumables Market, 2022-2035
20.4.3. 3D Cell Culture Services Market, 2022-2035

20.5. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
20.5.1. 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035
20.5.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035
20.5.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035

20.6. Global 3D Cell Culture Systems Market: Distribution by Type of Product
20.6.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035
20.6.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035
20.6.3 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035
20.6.4. 3D Cell Culture Systems Market for Microcarriers, 2022-2035
20.6.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035
20.6.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035
20.6.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2022-2035

20.7. Global 3D Cell Culture Systems Market: Distribution by Area of Application
20.7.1. 3D Cell Culture Systems Market for Cancer Research, 2022-2035
20.7.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035
20.7.3. 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035
20.7.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035

20.8. Global 3D Cell Culture Systems Market: Distribution by Purpose
20.8.1. 3D Cell Culture Systems Market for Research Use, 2022-2035
20.8.2 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035

20.9. Global 3D Cell Culture Systems Market: Distribution by Geography
20.9.1. 3D Cell Culture Systems Market in North America, 2022-2035
20.9.2 3D Cell Culture Systems Market in Europe, 2022-2035
20.9.3. 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035
20.9.4. 3D Cell Culture Systems Market in Latin America, 2022-2035
20.9.5. 3D Cell Culture Systems Market in Middle East and North Africa, 2022-2035
20.9.6. 3D Cell Culture Systems Market in Rest of the World, 2022-2035

21. SURVEY ANALYSIS
21.1. Chapter Overview
21.2. Overview of Respondents
21.2.1. Designation of Respondents

21.3. Survey Insights
21.3.1. 3D Cell Culture Format
21.3.2. Type of Product(s) Offered
21.3.3. Status of Development of Product(s)
21.3.4. Source of 3D Cultured Cells
21.3.5. Method Used for Fabrication
21.3.6. Area(s) of Application
21.3.7. Services Offered for 3D Cell Cultures
21.3.8. Current and Future Market Opportunity

22. CONCLUSION

23. EXECUTIVE INSIGHTS
23.1. Chapter Overview

23.2. Cellendes 
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Brigitte Angres, Co-founder

23.3. Synthecon 
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Bill Anderson, President and Chief Executive Officer

23.4. Anonymous 
23.4.1. Interview Transcript: Anonymous, President and Chief Executive Officer

23.5. Anonymous 
23.5.1. Interview Transcript: Anonymous, Co-founder and Vice President

23.6. BRTI Life Sciences 
23.6.1. Company Snapshot
22.6.2. Interview Transcript: Scott Brush, Vice President

23.7. Kirkstall
23.7.1. Company Snapshot
23.7.2. Interview Transcript: Malcolm Wilkinson, Non-Executive Director

23.8. QGel
23.8.1. Company Snapshot
23.8.2. Interview Transcript: Ryder Clifford, Chief Executive Officer and Simone Carlo Rizzi, Chief Scientific Officer

23.9. Xylyx Bio
23.9.1. Company Snapshot
23.9.2. Interview Transcript: Tanya Yankelevich, Former Director of Product Management and Business Development

23.10. InSphero 
23.10.1. Company Snapshot
23.10.2. Interview Transcript: Jens Kelm, Former Chief Scientific Officer

23.11. GSI
23.11.1. Company Snapshot
23.11.2. Interview Transcript: Walter Tinganelli, Group Leader, Clinical Radiobiology

23.12. Nanofiber Solutions 
23.12.1. Company Snapshot
23.12.2. Interview Transcript: Darlene Thieken, Former Project Manager

23.13. FlexCell International
23.13.1. Company Snapshot
23.13.2. Interview Transcript: Andrea Picon, Director of Business Development

23.14. InSphero
23.14.1. Company Snapshot
23.14.2. Interview Transcript: Frank Junker, Chief Business officer

23.15. MBL International
23.15.1. Company Snapshot
23.15.2. Interview Transcript: Mamun, Rahman, Manger, Business Development

24. APPENDIX I: TABULATED DATA

25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Classification of Cell Cultures
Figure 3.2 Types of Cell Cultures
Figure 3.3 Key Components of ECM
Figure 3.4 Factors Influencing the Selection of 3D Cell Culture Systems
Figure 3.5 Methods Used for Isolation of Cells from Tissues
Figure 3.6 Methods Used for Cryogenic Storage of Cell Cultures
Figure 3.7 Biosafety Levels for Cell Cultures
Figure 3.8 Key Applications of Cell Cultures
Figure 3.9 Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
Figure 3.10 Advantages and Limitations of 3D Cell Culture Systems
Figure 4.1 Classification of 3D Cell Culture Systems
Figure 4.2 Natural Components of ECM Used for Fabrication of Scaffolds
Figure 4.3 Advantages and Disadvantages of Hydrogels
Figure 4.4 Advantages of Microcarriers
Figure 4.5 Techniques Used for Formation of 3D Spheroids
Figure 4.6 Structures of Spinner Flask and Rotating Wall Bioreactors
Figure 6.1 3D Cell Culture System Developers: Distribution by Year of Establishment
Figure 6.2 3D Cell Culture System Developers: Distribution by Company Size
Figure 6.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Figure 6.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Figure 6.5 3D Cell Culture System Developers: Distribution by Type of Product
Figure 6.6 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Figure 6.7 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 6.8 World Map Representation: Distribution by Location of Headquarters
Figure 7.1 Scaffold Based Products: Distribution by Status of Development
Figure 7.2 Scaffold Based Products: Distribution by Type of Product
Figure 7.3 Scaffold Based Products: Distribution by Source of Scaffold
Figure 7.4 Scaffold Based Products: Distribution by Material Used for Fabrication
Figure 7.5 Scaffold Based Products: Distribution by Type of Product and Source of Scaffold
Figure 7.6 Scaffold Based Products: Distribution by Type of Product and Material Used for Fabrication
Figure 7.7 Scaffold Based Product Developers: Distribution by Year of Establishment
Figure 7.8 Scaffold Based Product Developers: Distribution by Company Size
Figure 7.9 Scaffold Based Product Developers: Distribution by Location of Headquarters
Figure 7.10 Leading Developers: Distribution by Number of Scaffold Based Products
Figure 7.11 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 8.1 Scaffold Free Products: Distribution by Status of Development
Figure 8.2 Scaffold Free Products: Distribution by Type of Product
Figure 8.3 Scaffold Free Products: Distribution by Method Used for Fabrication
Figure 8.4 Scaffold Free Products: Distribution by Material Used for Fabrication
Figure 8.5 Scaffold Free Products: Distribution by Type of Product and Material Used for Fabrication
Figure 8.6 Scaffold Free Product Developers: Distribution by Year of Establishment
Figure 8.7 Scaffold Free Product Developers: Distribution by Company Size
Figure 8.8 Scaffold Free Product Developers: Distribution by Location of Headquarters
Figure 8.9 Leading Developers: Distribution by Number of Scaffold Free Products
Figure 8.10 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 9.1 3D Bioreactors: Distribution by Type of 3D Bioreactor
Figure 9.2 3D Bioreactors: Distribution by Status of Development
Figure 9.3 3D Bioreactors: Distribution by Working Volume
Figure 9.4 3D Bioreactors: Distribution by Scale of Operation
Figure 9.5 3D Bioreactors: Distribution by Manufacturing Process
Figure 9.6 3D Bioreactors: Distribution by Type of Cell Culture System
Figure 9.7 3D Bioreactors: Distribution by Type of Molecule Processed
Figure 9.8 3D Bioreactors: Distribution by Area of Application
Figure 9.9 3D Bioreactor Developers: Distribution by Year of Establishment
Figure 9.10 3D Bioreactor Developers: Distribution by Company Size
Figure 9.11 3D Bioreactor Developers: Distribution by Location of Headquarters
Figure 9.12 Leading Developers: Distribution by Number of 3D Bioreactors
Figure 10.1 Key Application Areas of 3D Cell Culture Systems
Figure 10.2 3D Cell Culture Systems in Cancer Research
Figure 10.3 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
Figure 10.4 Methods to Generate Embryoid Bodies
Figure 10.5 Top-Down and Bottom-Up Approaches for Tissue Engineering
Figure 10.6 3D Cell Culture Systems: Distribution by Key Application Areas
Figure 10.7 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Figure 10.8 Scaffold Based 3D Products: Distribution by Key Application Areas
Figure 10.9 Scaffold Free 3D Products: Distribution by Key Application Areas
Figure 10.10 3D Bioreactors: Distribution by Key Application Areas
Figure 13.1 Key Features of 3D Perfusion Bioreactors
Figure 13.2 MagDrive and AirDrive Mechanisms for PBS Bioreactors
Figure 13.3 Advantages of Rotary Cell Culture System (RCCS)
Figure 14.1 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015 - 2021
Figure 14.2 Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 – 2021
Figure 14.3 Funding and Investments: Cumulative Amount Invested, 2015 – 2021 (USD Million)
Figure 14.4 Funding and Investments: Distribution of Instances by Type of Funding, 2015 –2021
Figure 14.5 Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 – 2021
Figure 14.6 Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 – 2021 (USD Million)
Figure 14.7 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 – 2021
Figure 14.8 Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 – 2021
Figure 14.9 Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 – 2021
Figure 14.10 Funding and Investments: Distribution by Geography
Figure 14.11 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 – 2021
Figure 14.12 Most Active Players: Distribution by Number of Funding Instances, 2015 –2021
Figure 14.13 Most Active Players: Distribution by Amount Raised, 2015 – 2021 (USD Million)
Figure 14.14 Most Active Investors: Distribution by Number of Funding Instances, 2015 –2021
Figure 14.15 Funding and Investment Summary, 2015 – 2021 (USD Million)
Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 – 2021
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 15.8 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Figure 15.9 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Figure 15.10 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Figure 15.11 Partnerships and Collaborations: Distribution by Type of Product
Figure 15.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 15.13 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 15.14 Most Active Players: Distribution by Number of Partnerships
Figure 15.15 Partnerships and Collaborations: Regional Distribution
Figure 15.16 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 Patent Analysis: Cumulative Distribution by Publication Year, 2016 – Q1 2022
Figure 16.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2016 – Q1 2022
Figure 16.4 Patent Analysis: Distribution of Filed Patents Publication Year, 2016 – Q1 2022
Figure 16.5 Patent Analysis: Distribution by Type of Patent and Publication Year, 2016 – Q1 2022
Figure 16.6 Patent Analysis: Distribution by Issuing Authority
Figure 16.7 Patent Analysis: Distribution by CPC Symbols
Figure 16.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2016 – Q1 2022
Figure 16.9 Word Cloud Analysis: Distribution by Emerging Focus Area
Figure 16.10 Leading Industry Players: Distribution by Number of Patents
Figure 16.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.12 Patent Analysis: Distribution by Patent Age, 2002-2022
Figure 16.13 Patent Analysis: Distribution by Relatuve Valuation
Figure 17.1 Publication Analysis: Distribution by Year of Publication
Figure 17.2 Word Cloud Analysis: Emerging Focus Areas
Figure 17.3 Top Authors: Distribution by Number of Publications
Figure 17.4 Key Journals: Distribution by Number of Publications
Figure 17.5 Key Publishers: Distribution by Number of Publications
Figure 17.6 Leading Funding Institutes: Distribution by Number of Publications
Figure 18.1 Competitiveness Analysis: 3D Bioreactors Developers based in North America
Figure 18.2 Competitiveness Analysis: 3D Bioreactors Developers based in Europe
Figure 18.3 Competitiveness Analysis: 3D Bioreactors Developers based in Asia-Pacific and Rest of the World
Figure 19.1 Organoids and Organ-on-Chips: Distribution by Status of Development
Figure 19.2 Organoids and Organ-on-Chips: Distribution by Application Area
Figure 19.3 Organoids and Organ-on-Chips Developers: Distribution by Year of Establishment
Figure 19.4 Organoids and Organ-on-Chips Developers: Distribution by Company Size
Figure 19.5 Organoids and Organ-on-Chips Developers: Distribution by Location of Headquarters
Figure 20.1 Global 3D Cell Culture Market, 2022-2035 (USD Million)
Figure 20.2 Global 3D Cell Culture Market: Distribution by Business Segment, 2022 and 2035
Figure 20.3 3D Cell Culture Systems Market, 2022-2035 (USD Million)
Figure 20.4 3D Cell Culture Consumables Market, 2022-2035 (USD Million)
Figure 20.5 3D Cell Culture Services Market, 2022-2035 (USD Million)
Figure 20.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2022-2035
Figure 20.7 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035 (USD Million)
Figure 20.8 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035 (USD Million)
Figure 20.9 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035 (USD Million)
Figure 20.10 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2022 and 2035
Figure 20.11 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035 (USD Million)
Figure 20.12 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035 (USD Million)
Figure 20.13 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035 (USD Million)
Figure 20.14 3D Cell Culture Systems Market for Microcarriers, 2022-2035 (USD Million)
Figure 20.15 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035 (USD Million)
Figure 20.16 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035 (USD Million)
Figure 20.17 3D Cell Culture Systems Market for Suspension Cultures, 2022-2035 (USD Million)
Figure 20.18 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2022 and 2035
Figure 20.19 3D Cell Culture Systems Market for Cancer Research, 2022-2035 (USD Million)
Figure 20.20 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035 (USD Million)
Figure 20.21 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035 (USD Million)
Figure 20.22 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035 (USD Million)
Figure 20.23 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2022 and 2035
Figure 20.24 3D Cell Culture Systems Market for Research Use, 2022-2035 (USD Million)
Figure 20.25 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035 (USD Million)
Figure 20.26 Global 3D Cell Culture Systems Market: Distribution by Geography, 2022 and 2035
Figure 20.27 3D Cell Culture Systems Market in North America, 2022-2035 (USD Million)
Figure 20.28 3D Cell Culture Systems Market in Europe, 2022-2035 (USD Million)
Figure 20.29 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 20.30 3D Cell Culture Systems Market in Latin America, 2022-2035 (USD Million)
Figure 20.31 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2022-2035 (USD Million)
Figure 20.32 3D Cell Culture Systems Market in Rest of the World, 2022-2035 (USD Million)
Figure 20.33 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2022
Figure 20.34 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2022, 2028 and 2035 (USD Million)
Figure 21.1 Survey Insights: Distribution of Respondents by Year of Establishment of the Company
Figure 21.2 Survey Insights: Distribution of Respondents by Company Size
Figure 21.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Figure 21.4 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Figure 21.5 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Figure 21.6 Survey Insights: Distribution by Focus Area
Figure 21.7 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Figure 21.8 Survey Insights: Distribution by Status of Development of Product(s)
Figure 21.9 Survey Insights: Distribution by Method of Fabrication Used
Figure 21.10 Survey Insights: Distribution by Source of Cultured Cells
Figure 21.11 Survey Insights: Distribution by Key Applications
Figure 21.12 Survey Insights: Distribution by 3D Cell Culture Services Offered
Figure 21.13 Survey Insights: Distribution by Current and Future Market Opportunity, 2022 and 2035
Figure 22.1 Concluding Remarks: Overall Market Landscape of 3D Cell Culture Systems Market
Figure 22.2 Concluding Remarks: Funding and Investments
Figure 22.3 Concluding Remarks: Partnerships and Collaborations
Figure 22.4 Concluding Remarks: Patent Analysis
Figure 22.5 Concluding Remarks: Publication Analysis
Figure 22.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Morphology of Cells in a Culture
Table 3.2 Differences between 2D and 3D Cell Cultures
Table 3.3 Features of 3D Spheroids generated via 3D Cell Culture Systems
Table 4.1 Advantages and Disadvantages of Scaffold Based and Scaffold Free Systems
Table 4.2 Advantages and Disadvantages of Natural and Synthetic Scaffolds
Table 4.3 Advantages and Disadvantages of Natural and Synthetic Hydrogels
Table 4.4 Cell Cultures Used in Magnetic Levitation
Table 4.5 Origin and Culture Techniques Used for Organoids
Table 5.1 Advantages and Disadvantages of Methods Used for Fabrication for Porous Scaffolds
Table 5.2 3D Cell Culture Studies Using Porous Scaffolds
Table 5.3 Methods for Fabrication Used of Fibrous Scaffolds
Table 5.4 Advantages and Disadvantages of Methods Used for Fabrication of Fibrous Scaffolds
Table 5.5 3D Cell Culture Studies Using Fibrous Scaffolds
Table 5.6 Advantages and Disadvantages of Methods Used for Fabrication of Hydrogels
Table 5.7 3D Cell Culture Studies Using Hydrogels
Table 5.8 Advantages and Disadvantages of Methods Used for Fabrication of Custom Scaffolds
Table 5.9 3D Cell Culture Studies Using Custom Scaffolds
Table 5.10 Advantages and Disadvantages of Methods Used for Fabrication of Microspheres
Table 5.11 3D Cell Culture Studies Using Microspheres
Table 5.12 3D Cell Culture Studies Using Native Scaffolds
Table 6.1 3D Cell Culture Systems: List of Developers
Table 6.2 3D Cell Culture Systems: List of Service Providers
Table 6.3 3D Cell Culture Systems: List of Assays, Kits and Reagents
Table 7.1 Scaffold Based Products: List of Products
Table 7.2 Scaffold Based Products: List of Developers
Table 8.1 Scaffold Free Products: List of Products
Table 8.2 Scaffold Free Products: List of Developers
Table 9.1 3D Bioreactors: List of Products
Table 9.2 3D Bioreactors: List of Developers
Table 10.1 Scaffold Based Products: Information on Key Application Areas
Table 10.2 Scaffold Free Products: Information on Key Application Areas
Table 10.3 3D Bioreactors: Information on Key Application Areas
Table 11.1 Scaffold Based Products (Hydrogel / ECM Developers): List of Companies Profiled
Table 11.2 3D Biotek: Company Snapshot
Table 11.3 3D Biotek: Key Characteristics of Hydrogels / ECMs
Table 11.4 3D Biotek: Recent Developmnets and Future Outlook
Table 11.5 Advanced BioMatrix: Company Snapshot
Table 11.6 Advanced BioMatrix: Key Characteristics of Hydrogels / ECMs
Table 11.7 Advanced BioMatrix: Recent Developments and Future Outlook
Table 11.8 Alphabioregen: Company Snapshot
Table 11.9 Alphabioregen: Key Characteristics of Hydrogels / ECMs
Table 11.10 Alphabioregen: Recent Developments and Future Outlook
Table 11.11 Corning Life Sciences: Company Snapshot
Table 11.12 Corning Life Sciences: Key Characteristics of Hydrogels / ECMs
Table 11.13 Corning Life Sciences: Recent Developments and Future Outlook
Table 11.14 REPROCELL: Company Snapshot
Table 11.15 REPROCELL: Key Characteristics of Hydrogels / ECMs
Table 11.16 REPROCELL: Recent Developments and Future Outlook
Table 12.1 Scaffold Free Products (Organ-on-Chips): List of Companies Profiled
Table 12.2 CN Bio Innovations: Company Snapshot
Table 12.3 CN Bio Innovations: Information on Financial Instances
Table 12.4 CN Bio Innovations: Key Characteristics of Organ-on-Chips Products
Table 12.5 CN Bio Innovations: Recent Developments and Future Outlook
Table 12.6 Emulate: Company Snapshot
Table 12.7 Emulate: Information on Funding Instances
Table 12.8 Emulate: Key Characteristics of Organ-on-Chips Products
Table 12.9 Emulate: Recent Developments and Future Outlook
Table 12.10 InSphero: Company Snapshot
Table 12.11 InSphero: Information on Funding Instances
Table 12.12 InSphero: Key Characteristics of Organ-on-Chips Products
Table 12.13 InSphero: Recent Developments and Future Outlook
Table 12.14 MIMETAS: Company Snapshot
Table 12.15 MIMETAS: Information on Funding Instances
Table 12.16 MIMETAS: Key Characteristics of Organ-on-Chips Products
Table 12.17 MIMETAS: Recent Developments and Future Outlook
Table 12.18 TissUse: Company Snapshot
Table 12.19 TissUse: Key Characteristics of Organ-on-Chips Products
Table 12.20 TissUse: Recent Developments and Future Outlook
Table 13.1 3D Bioreactors: List of Companies Profiled
Table 13.2 BISS TGT: Company Snapshot
Table 13.3 BISS TGT: Key Characteristics of 3D Bioreactors
Table 13.4 BISS TGT: Recent Developments and Future Outlook
Table 13.5 Celartia: Company Snapshot
Table 13.6 Celartia: Key Characteristics of 3D Bioreactors
Table 13.7 Celartia: Recent Developments and Future Outlook
Table 13.8 Cell Culture: Company Snapshot
Table 13.9 Cell Culture: Key Characteristics of 3D Bioreactors
Table 13.10 EBERS: Company Snapshot
Table 13.11 EBERS: Key Characteristics of 3D Bioreactors
Table 13.12 EBERS: Recent Developments and Future Outlook
Table 13.13 Flexcell International: Company Snapshot
Table 13.14 Flexcell International: Key Characteristics of 3D Bioreactors
Table 13.15 Flexcell International: Recent Developments and Future Outlook
Table 13.16 PBS Biotech: Company Snapshot
Table 13.17 PBS Biotech: Key Characteristics of 3D Bioreactors
Table 13.18 PBS Biotech: Recent Developments and Future Outlook
Table 13.19 Synthecon: Company Snapshot
Table 13.20 Synthecon: Key Characteristics of 3D Bioreactors
Table 13.21 Synthecon: Recent Developments and Future Outlook
Table 14.1 Funding and Investments: Information on Year of Investment, Type of Funding, Amount Raised and Investor, 2016 – 2021
Table 14.2 Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Focus Area, and Type of Product, 2016 –2021
Table 15.1 Partnerships and Collaborations: Information on Year of Partnership, Type of Partnership, and Partner, 2016 – Q1 2022
Table 15.2 Partnerships and Collaborations: Information on Type of Agreement, Focus Area, and Type of Product, 2016 – Q1 2022
Table 16.1 Patent Analysis: CPC Symbols
Table 16.2 Patent Analysis: Most Popular CPC Symbols
Table 16.3 Patent Analysis: List of Top 10 CPC Symbols
Table 16.4 Patent Analysis: List of Relatively High Value Patents
Table 18.1 Survey Insights: Overview of Respondents
Table 18.2 Survey Insights: Designation and Seniority Level
Table 18.3 Survey Insights: Focus Area of the Company
Table 18.4 Survey Insights: Type of 3D Cell Culture Products Offered
Table 18.5 Survey Insights: Status of Development of Product(s)
Table 18.6 Survey Insights: Method of Fabrication Used
Table 18.7 Survey Insights: Source of 3D Cultured Cells
Table 18.8 Survey Insights: Key Areas of Application
Table 18.9 Survey Insights: 3D Cell Culture Services Offered
Table 18.10 Survey Insights: Current Market Opportunity (2022)
Table 18.11 Survey Insights: Future Market Opportunity (2035)
Table 20.1 Cellendes: Company Snapshot
Table 20.2 Synthecon: Company Snapshot
Table 20.3 BRTI Life Sciences: Company Snapshot
Table 20.4 Kirkstall: Company Snapshot
Table 20.5 QGel: Company Snapshot
Table 20.6 Xylyx Bio: Company Snapshot
Table 20.7 InSphero: Company Snapshot
Table 20.8 GSI: Company Snapshot
Table 20.9 Nanofiber Solutions: Company Snapshot
Table 20.10 FlexCell International: Company Snapshot
Table 20.11 MBL International: Company Snapshot
Table 21.1 3D Cell Culture System Developers: Distribution by Year of Establishment
Table 21.2 3D Cell Culture System Developers: Distribution by Company Size
Table 21.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Table 21.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Table 21.5 3D Cell Culture System Developers: Distribution by Type of Product
Table 21.6 3D Cell Culture System Developers: Distribution by Number of Products
Table 21.7 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Table 21.8 Tree Map Representation: Distribution by Company Size and Type of Product
Table 21.9 World Map Representation: Distribution by Location of Regional Headquarters
Table 21.10 Scaffold Based Products: Distribution by Status of Development
Table 21.11 Scaffold Based Products: Distribution by Type of Product
Table 21.12 Scaffold Based Products: Distribution by Source of 3D Cultured Cells
Table 21.13 Scaffold Based Products: Distribution by Method Used for Fabrication
Table 21.14 Scaffold Based Products: Distribution by Material Used for Fabrication
Table 21.15 Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.16 Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.17 Scaffold Based Product Developers: Distribution by Year of Establishment
Table 21.18 Scaffold Based Product Developers: Distribution by Company Size
Table 21.19 Scaffold Based Product Developers: Distribution by Location of Headquarters
Table 21.20 Leading Developers: Distribution by Number of Scaffold Based Products
Table 21.21 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.22 Scaffold Free Products: Distribution by Status of Development
Table 21.23 Scaffold Free Products: Distribution by Type of Product
Table 21.24 Scaffold Free Products: Distribution by Source of 3D Cultured Cells
Table 21.25 Scaffold Free Products: Distribution by Method Used for Fabrication
Table 21.26 Scaffold Free Products: Distribution by Material Used for Fabrication
Table 21.27 Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.28 Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.29 Scaffold Free Product Developers: Distribution by Year of Establishment
Table 21.30 Scaffold Free Product Developers: Distribution by Company Size
Table 21.31 Scaffold Free Product Developers: Distribution by Location of Headquarters
Table 21.32 Leading Developers: Distribution by Number of Scaffold Free Products
Table 21.33 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.34 3D Bioreactors: Distribution by Type of 3D Bioreactor
Table 21.35 3D Bioreactors: Distribution by Working Volume
Table 21.36 3D Bioreactor Developers: Distribution by Year of Establishment
Table 21.37 3D Bioreactor Developers: Distribution by Company Size
Table 21.38 3D Bioreactor Developers: Distribution by Location of Headquarters
Table 21.39 Leading Developers: Distribution by Number of 3D Bioreactors
Table 21.40 3D Cell Culture Systems: Distribution by Key Application Areas
Table 21.41 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Table 21.42 Scaffold Based Products: Distribution by Key Application Areas
Table 21.43 Scaffold Free Products: Distribution by Key Application Areas
Table 21.44 3D Bioreactors: Distribution by Key Application Areas
Table 21.45 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015 - 2021
Table 21.46 Funding and Investments: Cumulative Number of Instances by Year, 2015 – 2021
Table 21.47 Funding and Investments: Cumulative Amount Invested, 2015 – 2021 (USD Million)
Table 21.48 Funding and Investments: Distribution of Instances by Type of Funding, 2015 –2021
Table 21.49 Funding and Investments: Year-Wise Distribution by Number of Instances and Type of Funding, 2015 – 2021
Table 21.50 Funding and Investments: Distribution of Amount Invested by Type of Funding, 2015 – 2021 (USD Million)
Table 21.51 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 –2021
Table 21.52 Funding and Investments: Distribution of Instances and Amount Invested by 3D Cell Culture Format, 2015 – 2021
Table 21.53 Funding and Investments: Distribution of Instances and Amount Invested by Type of Product, 2015 – 2021
Table 21.54 Funding and Investments: Distribution by Geography
Table 21.55 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 – 2021
Table 21.56 Most Active Players: Distribution by Number of Funding Instances, 2015 – 2021
Table 21.57 Most Active Players: Distribution by Amount Raised, 2015 – 2021 (USD Million)
Table 21.58 Most Active Investors: Distribution by Funding Instances, 2015 – 2021
Table 21.59 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - 2021
Table 21.60 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.61 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 21.62 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 21.63 Partnerships and Collaborations: Distribution by Type of Partner
Table 21.64 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.65 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.66 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Table 21.67 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Table 21.68 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Table 21.69 Partnerships and Collaborations: Distribution by Type of Product
Table 21.70 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Table 21.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 21.72 Most Active Players: Distribution by Number of Partnerships
Table 21.73 Partnerships and Collaborations: Regional Distribution
Table 21.74 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 21.75 Patent Analysis: Distribution by Type of Patent
Table 21.76 Patent Analysis: Cumulative Distribution by Publication Year, 2016 - Q1 2022
Table 21.77 Patent Analysis: Distribution of Granted Patents by Publication Year, 2016-Q1 2022
Table 21.78 Patent Analysis: Distribution of Filed Patents Publication Year, 2016-Q1 2022
Table 21.79 Patent Analysis: Distribution by Number of Patent Type and Publication Year, 2016-Q1 2022
Table 21.80 Patent Analysis: Distribution by Issuing Authorities Involved
Table 21.81 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2016-Q1 2022
Table 21.82 Leading Industry Players: Distribution by Number of Patents
Table 21.83 Leading Non-Industry Players: Distribution by Number of Patents
Table 21.84 Patent Analysis: Distribution by Patent Age, 2002-2022
Table 21.85 Patent Analysis: Valuation Analysis
Table 21.86 Publication Analysis: Distribution by Publication Year, 2019-Q1 2022
Table 21.87 Top Authors: Analysis by Number of Publications
Table 21.88 Patent Analysis: Key Journals based on Number of Publications
Table 21.89 Patent Analysis: Key Publisher based on Number of Publications
Table 21.90 Leading Funding Institute: Distribution by Number of Publications
Table 21.91 Global 3D Cell Culture Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.92 Global 3D Cell Culture Market: Distribution by Business Segment, 2022 and 2035
Table 21.93 3D Cell Culture Systems Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.94 3D Cell Culture Consumables Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.95 3D Cell Culture Services Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.96 Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2022 and 2035
Table 21.97 3D Cell Culture Systems Market for Scaffold based Products, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.98 3D Cell Culture Systems Market for Scaffold Free Products, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.99 3D Cell Culture Systems Market for Market 3D Bioreactors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.100 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2022 and 2035
Table 21.101 3D Cell Culture Systems Market for Attachment Resistant Surfaces, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.102 3D Cell Culture Systems Market for Hydrogels / ECMs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.103 3D Cell Culture Systems Market for Micropatterned Surface, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.104 3D Cell Culture Systems Market for Microcarriers, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.105 3D Cell Culture Systems Market for Microfluidic Systems, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.106 3D Cell Culture Systems Market for Solid Scaffolds, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.107 3D Cell Culture Systems Market for Suspension Culture Systems, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.108 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2022 and 2035
Table 21.109 3D Cell Culture Systems Market for Cancer Research, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.110 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.111 3D Cell Culture Systems Market for Stem Cell Research, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.112 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.113 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2022 and 2035
Table 21.114 3D Cell Culture Systems Market for Research Use, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.115 3D Cell Culture Systems Market for Therapeutic Use, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.116 Global 3D Cell Culture Systems Market: Distribution by Geography, 2022 and 2035
Table 21.117 3D Cell Culture Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.118 3D Cell Culture Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.119 3D Cell Culture Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.120 3D Cell Culture Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Million)
Table 21.121 3D Cell Culture Systems Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.122 3D Cell Culture Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 21.123 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2022
Table 21.124 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2022, 2028 and 2035 (USD Million)
Table 21.125 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 21.126 Survey Insights: Distribution of Respondents by Company Size
Table 21.127 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Table 21.128 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Table 21.129 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Table 21.130 Survey Insights: Distribution by Focus Area
Table 21.131 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Table 21.132 Survey Insights: Distribution by Development Status of Product(s)
Table 21.133 Survey Insights: Distribution by Method of Fabrication Used
Table 21.134 Survey Insights: Distribution by Source of Cultured Cells
Table 21.135 Survey Insights: Distribution by Key Application Areas
Table 21.136 Survey Insights: Distribution by 3D Cell Culture Services Offered
Table 21.137 Survey Insights: Distribution by Current and Future Market Opportunity, 2022 and 2035

List Of Companies

The following companies and organizations have been mentioned in the report

  1. 101Bio
  2. 3D Biomatrix
  3. 3D Biotechnology Solutions
  4. 3D Biotek
  5. 3Dnamics
  6. 4Dcell
  7. 4titude
  8. AbbVie Ventures
  9. abc biopply
  10. Abcam
  11. ABL Europe
  12. Åbo Akademi University
  13. Abstraction Ventures
  14. Abzena
  15. Accellta
  16. Accurate International Biotechnology
  17. Advanced BioMatrix
  18. Advanced Regenerative Manufacturing Institute (ARMI)/BiofabUSA
  19. Advanced Scientifics
  20. Aetos Biologics
  21. Afirmus Biosource
  22. AGC
  23. Agency for Science, Technology and Research (A*STAR)
  24. AIM Biotech
  25. Akero Therapeutics
  26. Akron Biotech
  27. Alector
  28. Allevi
  29. Alnylam Pharmaceuticals
  30. Alphabioregen
  31. ALS Investment Fund
  32. AlveoliX
  33. American Laboratory Products
  34. AMS Biotechnology
  35. AnaPath Services
  36. Angel Investors
  37. AngelMD
  38. Angels 5K
  39. Angels in MedCity
  40. Angels Santé
  41. Anthrogenesis
  42. Aquitaine Science Transfert
  43. Aquiti Gestion
  44. AR Brown
  45. Arizona State University
  46. ARL Design
  47. ARTeSYN Biosolutions
  48. AS ONE INTERNATIONAL
  49. AstraZeneca
  50. Arizona State University
  51. ATEL Ventures
  52. Atera
  53. Avantor
  54. Axol Bioscience
  55. AxoSim
  56. AXT
  57. Axxicon
  58. BASF
  59. Bayer
  60. B-CULTURE
  61. BEOnChip
  62. Bi/ond
  63. Bio-Byblos Biomedical
  64. BioCat
  65. BioConcept
  66. BIOFABICS
  67. Biogelx
  68. Bioinspired Solutions
  69. BioInvent International
  70. BIOKÉ
  71. BioLamina
  72. Biomaterials USA
  73. Biomerix
  74. BiomimX
  75. Biopredic International
  76. Bio-Techne
  77. BioTek Instruments
  78. BISS TGT
  79. Barcelona Liver Bioservices (BLB)
  80. Bonus BioGroup
  81. Bpifrance
  82. BRAIN
  83. BrainXell
  84. Brammer Bio
  85. Braveheart Investment Group
  86. Bristol-Myers Squibb
  87. Broad Institute
  88. BRTI Life Sciences
  89. Cambridge Bioscience
  90. CarThera
  91. Cedars-Sinai Medical Center
  92. Celartia
  93. Cell Applications
  94. Cell Culture Company (C3)
  95. CellFiber
  96. Cell Guidance Systems
  97. CELLEC Biotek
  98. Cellendes
  99. Cellevate
  100. CELLnTEC
  101. CELLphenomics
  102. CellSpring
  103. CellSystems
  104. Celprogen
  105. CelVivo
  106. Center for Drug Evaluation and Research (CDER)
  107. Center for the Advancement of Science in Space (CASIS)
  108. CESCO Bioengineering
  109. Charles River Laboratories
  110. Cherry Biotech
  111. China Regenerative Medicine International (CRMI)
  112. Cincinnati Children's Hospital Medical Center
  113. CITIC Securities
  114. CN Bio Innovations
  115. CN Innovations
  116. Collagen Solutions
  117. Commission for Technology and Innovation
  118. Commonwealth Serum Laboratories
  119. Comune di Milano
  120. Corning Life Sciences
  121. Cosmo Bio
  122. Creative Bioarray
  123. CSL
  124. Curi Bio
  125. Cyprio
  126. Cyprotex
  127. Cytiva
  128. Danaher
  129. Deepbridge Capital
  130. Demcon
  131. Development Bank of Wales
  132. DiPole Materials
  133. Downing Ventures
  134. Dynamic42
  135. EBERS
  136. Ectica Technologies
  137. EDITHGEN
  138. EDmicBio
  139. Electrospinning
  140. Emulate
  141. Enso Discoveries
  142. eNUVIO
  143. Eppendorf
  144. Esco Aster
  145. Esperante
  146. Ethicon
  147. Etica Technologies
  148. European Commission
  149. European Life Sciences Growth Fund (ELSGF)
  150. European Research Council (ERC)
  151. European Union (EU)
  152. Eurostars
  153. EU-ToxRisk
  154. Eva Scientific
  155. Evotec
  156. Executive Agency for Small and Medium-sized Enterprises (EASME)
  157. faCellitate
  158. Food and Drug Administration
  159. Fennik Life Sciences
  160. Ferentis
  161. FHNW University
  162. FiberCell Systems
  163. Fibralign
  164. Finep
  165. Finesse Solutions
  166. Finovam Gestion
  167. Flexcell International
  168. Fundação para a Ciência e a Tecnologia (FCT)
  169. Foundation for Technological Innovation
  170. Founder
  171. Founders Fund
  172. Freeline
  173. French Government
  174. Frequency Therapeutics
  175. FroggaBio
  176. Fujifilm
  177. FUJIFILM Wako Pure Chemical
  178. Funakoshi
  179. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  180. Gabriel Investments
  181. Galapagos
  182. Galia Gestion
  183. Gamma 3
  184. Gelmetix
  185. Gelomics
  186. Gemini Bio
  187. Gemstone Biotherapeutics
  188. Genome Institute of Singapore
  189. Georgia Research Alliance
  190. German Research Foundation
  191. GlassWall Syndicate
  192. GlaxoSmithKline
  193. Global Cell Solutions
  194. Government of China
  195. Government of the Netherlands
  196. Great Stuff Ventures
  197. GSI
  198. HµREL
  199. Hamilton
  200. Harvard Apparatus
  201. Harvard College
  202. HCS Pharma
  203. Helvoet
  204. Heraeus Medical
  205. Hesperos
  206. Histogenics
  207. Hokkaido Soda
  208. HP Wild Holding
  209. Hubrecht Organoid Technology
  210. Human Models for Analysis of Pathways (HMAPs) Center
  211. Humanetics
  212. Hyamedix
  213. ibidi
  214. IMSS-Gulf Bio Analytical
  215. INITIO CELL
  216. Innovate UK
  217. Innovation Fund Denmark
  218. InoCure
  219. Inova Health System
  220. inRegen
  221. InSphero
  222. Institute for Molecular Medicine Finland
  223. Invest Northern Ireland
  224. Invitrocue
  225. InvivoSciences
  226. Ionis Pharmaceuticals
  227. Irdi Soridec Gestion
  228. Janssen Biotech
  229. Japan Vilene Company
  230. Jellagen Marine Biotechnologies
  231. Johns Hopkins University
  232. JRI Orthopaedics
  233. JVCKENWOOD
  234. Kero
  235. Kim & Friends
  236. Kirkstall
  237. KIYATEC
  238. KOKEN
  239. Koninklijke Nederlandse Akademie Van Wetenschappen
  240. Kuraray
  241. LabCorp
  242. Laboratory for Integrated Micro Mechatronic Systems
  243. Laconia
  244. LAMBDA Laboratory Instruments
  245. Lantern Pharma
  246. Lawrence J. Ellison Institute for Transformative Medicine
  247. LBA Healthcare Management
  248. Lena Biosciences
  249. LFB Biomanufacturing
  250. Life Technologies
  251. Lifecore Biomedical
  252. LifeNet Health
  253. Laboratory for Integrated Micro-Mechatronic Systems (LIMMS)
  254. Lineage Cell Therapeutics
  255. Locate Bio
  256. London School of Hygiene & Tropical Medicine
  257. Lonza
  258. Lund University
  259. LuoLabs
  260. Manchester BIOGEL
  261. Mario Negri Institute for Pharmacological Research
  262. Maryland Momentum Fund
  263. Maryland Stem Cell Research Fund (MSCRF)
  264. Massachusetts Institute of Technology
  265. MassChallenge
  266. MatTek Life Sciences
  267. MBL International
  268. Menicon Life Science
  269. Merck Accelerator
  270. Merck KGaA
  271. Michael J. Fox Foundation
  272. Michigan Technological University
  273. MicorFIT
  274. MicroDigital
  275. Micronit
  276. MicroTissues
  277. Midven
  278. MIMETAS
  279. Minerva Business Angel Network
  280. Ministry of Higher Education, Research and Innovation (France)
  281. Mirage Biomedicals
  282. Molecular Devices
  283. MTTlab
  284. Nano Dimension
  285. Nanobiose
  286. Nanofiber Solutions
  287. Nanogaia
  288. NanoSurface Biomedical
  289. National Aeronautics and Space Administration (NASA)
  290. National Cancer Institute (NCI)
  291. National Center for Advancing Translational Sciences (NCATS)
  292. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
  293. National Institutes of Health (NIH)
  294. National Institute on Aging (NIA)
  295. National Institutes for Food and Drug Control (NIFDC)
  296. National Natural Science Foundation of China
  297. National Science Foundation (NSF)
  298. National University Hospital
  299. National University of Singapore
  300. NETRI
  301. Neuromics
  302. New Orleans BioFund
  303. Newable Private Investing
  304. Nexcelom Bioscience
  305. Nichirei Biosciences
  306. Nord France Amorquage
  307. Northwick Park Institute for Medical Research
  308. Nortis
  309. Nova Biomedical
  310. Novartis Venture Fund
  311. Noviocell
  312. Nucleus Biologics
  313. NYU Winthrop Hospital
  314. Olaregen Therapeutix
  315. Omni Life Science
  316. Oregon Health & Science University
  317. Organovo
  318. Orthomimetics
  319. OS Fund
  320. Oxford MEStar
  321. Pairnomix
  322. Pall Corporation
  323. Particle3D
  324. Path BioAnalytics
  325. PBS Biotech
  326. Peak Capital Advisors
  327. Pelo Biotech
  328. Pensees
  329. PepGel
  330. Percell Biolytica
  331. PerkinElmer
  332. Pfizer
  333. Phase Holographic Imaging (PHI)
  334. Pitch@Palace
  335. PL BioScience
  336. Plasticell
  337. Pluristem Therapeutics
  338. Portugal Ventures
  339. Precision Biologics
  340. Premedical Laboratories
  341. Primorigen Biosciences
  342. Principia SGR
  343. ProBio
  344. ProBioGen
  345. Prodizen
  346. PromoCell
  347. Protista International
  348. PT Rajawali Medika Mandiri
  349. QGel Bio
  350. QIAGEN 
  351. Quintech Life Sciences
  352. RASA
  353. React4life
  354. Real Research
  355. RealBio Technology
  356. Regemat3D
  357. Repligen
  358. ReproCell
  359. Research Without Animal Experiment
  360. Revivocell
  361. Rigenerand
  362. Roche
  363. RoosterBio
  364. Roswell Park Comprehensive Cancer Center
  365. Royal Netherlands Academy of Arts and Sciences
  366. Saguaro Technologies
  367. SAICO Biosystems
  368. Sanofi Ventures
  369. SARSTEDT
  370. Sartorius
  371. S-BIO
  372. Science and Technology Facilities Council (STFC)
  373. ScienCell
  374. ScienCell Research Laboratories
  375. SciFi VC
  376. SciKon Innovation
  377. Scinus Cell Expansion
  378. Scottish Investment Bank
  379. ScreenIn3D
  380. Seres Therapeutics
  381. Shanghai Cienle Medical Technology
  382. Shanghai Institute of Biochemistry and Cell Biology (SIBCB)
  383. Shanghai Institute of Materia Medica
  384. Siemens Technology
  385. Sigma-Aldrich
  386. SKE Research Equipment
  387. SmiLe Incubator
  388. SoloHill Engineering
  389. Sphere Fluidics
  390. Spheritech
  391. Spiber Technologies
  392. Stanford University
  393. Start-Up Chile
  394. State Key Laboratory of Experimental Hematology
  395. StemCell Systems
  396. STEMCELL Technologies
  397. Stemmatters
  398. StemoniX
  399. StemTek Therapeutics
  400. SUN bioscience
  401. Swiss Federal Laboratories for Materials Science and Technology
  402. SyndicateRoom
  403. Synthecon
  404. SynVivo
  405. TA Instruments
  406. Takeda
  407. Tampere University
  408. Tantti Laboratory
  409. tebu-bio
  410. Technical University of Berlin
  411. TEDCO
  412. Terumo
  413. Texas Tech University Health Sciences Center  (TTUHSC) 
  414. The Idea Village
  415. Mario Negri Institute for Pharmacological Research
  416. Thermo Fisher Scientific
  417. TheWell Bioscience
  418. Tianjin Weikai Biological Engineering
  419. Tissue Click
  420. TissueLabs
  421. TissUse
  422. Tokyo Future Style
  423. TPG
  424. TreeFrog Therapeutics
  425. Trevigen
  426. Triumvirate Environmental
  427. Twinhelix
  428. U.S. Small Business Administration (SBA)
  429. UK Innovation & Science Seed Fund
  430. UK Science and Technology Facilities Council
  431. United States Department of Defense
  432. University College London
  433. University Hospital Zurich (USZ)
  434. University of Alberta
  435. University of Arkansas for Medical Sciences
  436. University of Bath
  437. University of Brescia
  438. University of Bristol
  439. University of California
  440. University of Cambridge
  441. University of Central Florida
  442. University of Genoa
  443. University of Manchester
  444. University of Mannheim
  445. University of Milan
  446. University of Nottingham
  447. University of Sheffield
  448. University of Strathclyde
  449. University of Washington School of Pharmacy
  450. University of Zurich
  451. UPM Biomedicals
  452. UW Medicine
  453. VA Portland Health Care System
  454. Vanderbilt University
  455. Venture Kick
  456. Venturecraft
  457. VentureSouth
  458. Viscofan BioEngineering
  459. Visikol
  460. Vivo Biosciences
  461. VWR
  462. Wake Forest Institute for Regenerative Medicine
  463. Women Who Tech
  464. XAnge
  465. Xenos
  466. XP Biomed
  467. Xylyx Bio
  468. Zhejiang University
  469. zPREDICTA

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com